Table 3.
Summary of drugs in clinical trials targeting canonical HH signaling in cancer
| Drugs | Target protein | NCT | N | Status | Phase | Cancer |
|---|---|---|---|---|---|---|
| Vismodegib | ||||||
| Vismodegib | Smo | NCT02436408 | 35 | Completed | Phase IV | BCC |
| NCT01201915 | 74 | Completed | Phase II | BCC | ||
| NCT01267955 | 45 | Active | Phase II | Chondrosarcoma | ||
| NCT01367665 | 1232 | Completed | Phase II | BCC | ||
| NCT01700049 | 28 | Completed | Phase II | BCC | ||
| NCT01815840 | 229 | Completed | Phase II | BCC | ||
| NCT00739661 | 104 | Completed | Phase II | OC | ||
| NCT02366312 | 2 | Completed | Phase II | KCOT | ||
| NCT03052478 | 10 | Completed | Phase II | Stomach neoplasms | ||
| Vismodegib/Chemotherapy/Other | Smo | NCT01878617 | 660 | Active | Phase II | MB |
| Vismodegib/GSK2256098/Capivasertib/Abemaciclib | Smo/ FAK/ AKT / CDK | NCT02523014 | 124 | Recruiting | Phase II | Progressive meningiomas |
| Vismodegib+ Chemotherapy | Smo | NCT01835626 | 24 | Completed | Phase II | Locally advanced BCC; Skin cancer; CM |
| Vismodegib+ Chemotherapy | Smo | NCT02694224 | 40 | Recruiting | Phase II | TNBC |
| Vismodegib+ Pembrolizumab | Smo + PD-1 | NCT02690948 | 16 | Completed | Phase I-II | Metastatic or unresectable BCC |
| Vismodegib+ Ribavirin+ Decitabine | Smo | NCT02073838 | 23 | Completed | Phase II | AML |
| Vismodegib/Other targeted drugs | Smo | NCT02091141 | 670 | Completed | Phase II | Neoplasms |
| Vismodegib/Other targeted drugs | Smo | NCT03158389 | 350 | Recruiting | Phase I-II | Glioblastoma |
| Vismodegib/Other targeted drugs | Smo | NCT03297606 | 720 | Recruiting | Phase II | NHL; MM; Advanced solid tumors |
| Vismodegib+ Bevacizumab | Smo + VEGF | NCT00636610 | 199 | Completed | Phase II | Metastatic CRC |
| Vismodegib+ Gemcitabine Hydrochloride | Smo | NCT01064622 | 118 | Completed | Phase I-II | PC |
| Vismodegib+ Gemcitabine Hydrochloride+ nab-Paclitaxel | Smo | NCT01088815 | 98 | Completed | Phase II | PC |
| Vismodegib+ RO4929097 | Smo + Gamma-Secretase | NCT01154452 | 78 | Completed | Phase I-II | Advanced or metastatic sarcoma |
| Vismodegib+ Gemcitabine Hydrochloride | Smo | NCT01195415 | 25 | Completed | Phase II | PC |
| Sonidegib | ||||||
| Sonidegib | Smo | NCT03534947 | 10 | Recruiting | Phase II | BCC |
| NCT01708174 | 22 | Completed | Phase II | MB | ||
| NCT00961896 | 18 | Completed | Phase II | BCNS | ||
| NCT01125800 | 76 | Completed | Phase I-II | MB | ||
| NCT01350115 | 10 | Completed | Phase II | BCNS | ||
| Sonidegib+ Lenalidomide | Smo + Cereblon | NCT02086552 | 28 | Completed | Phase II | Recurrent/refractory PCM |
| Sonidegib+ Ribociclib | Smo + CDK4/6 | NCT03434262 | 68 | Active | Phase I | Refractory or recurrent MB |
| Sonidegib+ Radiotherapy+Chemotherapy | Smo | NCT04402073 | 205 | Recruiting | Phase II | MB |
| Saridegib | ||||||
| Saridegib | Smo | NCT02762084 | 17 | Completed | Phase II | BCNS |
| NCT02828111 | 36 | Completed | Phase II | BCC | ||
| Saridegib+ Gemcitabine | Smo | NCT01130142 | 122 | Completed | Phase I-II | PC |
| Glasdegib | ||||||
| Glasdegib | Smo | NCT01841333 | 31 | Completed | Phase II | AML |
| NCT01286467 | 23 | Completed | Phase I | Solid tumors | ||
| NCT01842646 | 35 | Completed | Phase II | MDS; CML | ||
| Glasdegib+ Temozolomide Oral Capsule | Smo | NCT03466450 | 75 | Active | Phase I-II | Glioblastoma |
| Glasdegib+ Chemotherapy | Smo | NCT01546038 | 255 | Completed | Phase II | AML |
| Glasdegib+ Other targeted drugs | Smo | NCT03390296 | 50 | Completed | Phase I-II | AML |
| Glasdegib+ Azacitidine | Smo | NCT04842604 | 15 | Completed | Phase III | AML; MDS; CML |
| Taladegib | ||||||
| Taladegib+ Chemotherapy | Smo | NCT02784795 | 94 | Completed | Phase I | Solid tumor; BC; CC; CCC; STS |
| TAK-441 | ||||||
| TAK-441 | Smo | NCT01204073 | 34 | Completed | Phase I | Nonhematologic malignancies |
| Itraconazole | ||||||
| Itraconazole | Smo | NCT01108094 | 29 | Completed | Phase II | BCC |
| NCT01787331 | 21 | Completed | Phase II | Prostate adenocarcinoma | ||
| NCT02354261 | 38 | Completed | Phase II | BCC | ||
| Itraconazole+ AZD9291 | Smo + EGFR | NCT02157883 | 39 | Completed | Phase I | Advanced/inoperable NSCLC |
| Itraconazole+ volasertib | Smo + PLK1 | NCT01772563 | 28 | Completed | Phase I | Neoplasms |
| Itraconazole+ Other drugs | Smo | NCT02770378 | 10 | Completed | Phase I | Glioblastoma |
| Vitamin D3 | ||||||
| Vitamin D3 | Smo | NCT02553447 | 197 | Active | Phase I | CLL; NHL |
| Vitamin D3+ Photodynamic Therapy | Smo | NCT03483441 | 37 | Active | Phase I | BCC; BCNS |
| Vitamin D+ Rituximab | Smo + CD20 | NCT03078855 | 211 | Active | Phase III | NHL |
| ATO | ||||||
| ATO + GO | Gli + CD33 | NCT00274781 | 30 | Completed | Phase II | Advanced MDS |
| ATO + GO + ATRA | Gli + CD33 | NCT01409161 | 151 | Recruiting | Phase II | APML |
BCC Basal cell carcinoma, OC ovarian cancer, BCNS Basal cell nevus syndrome, MB medulloblastoma, KCOT keratocystic odontogenic tumor, CRC colorectal cancer, CM cutaneous malignancy, TNBC triple negative breast cancer, AML acute myeloid leukemia, PCM plasma cell myeloma, NHL non-Hodgkin lymphoma, PC pancreatic cancer, MM multiple myeloma, CML chronic myelomonocytic leukemia, MDS myelodysplastic syndrome, EC esophageal cancer, BC breast cancer, CCC cholangiocarcinoma, CC colon cancer, STS soft tissue sarcoma, NSCLC non-small cell lung cancer, CLL chronic lymphocytic leukemia, APML acute promyelocytic leukemia